DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20184322

A study on the safety and tolerability of mycophenolate mofetil in patients with connective tissue disease

Subham Das, Prasanta Padhan

Abstract


Background: Connective tissue disorders (CTD) are mostly due to inflammatory and fibrotic tissue injury. Glucocorticoids and immunomodulators though useful but are toxic. Mycophenolate mofetil (MMF) is now being used successfully in many autoimmune diseases, but the safety of MMF in CTD patients is yet to be conclusively established.

Methods: The study was a retrospective record based observational one in patients of CTD satisfying the predetermined inclusion criteria. Various safety parameters were noted down from the observed records and analysed accordingly.

Results: The 120 case records of CTD patients were analysed for a specific set of safety parameters over the preceding one year. Diarrhoeal attacks were the most commonly encountered side effect (38.3%) of long term patients who were on mycophenolate therapy followed by infection.

Conclusions: Mycophenolate was found to be generally well tolerated in CTD patients with few reports of adverse events, but larger clinical trials are needed to conclusively establish its safety.


Keywords


Autoimmune disease, Connective tissue disorders, CTD, Immunomodulators, Mycophenolate mofetil

Full Text:

PDF

References


Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev. 1993;136:5-28.

Das S, Padhan P. An overview of the extraarticular involvement in rheumatoid arthritis and its management. J Pharmacol Pharmacother. 2017;8:81-6.

Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. New England J Med. 2000 Oct 19;343(16):1156-62.

Nowack R, Göbel U, Klooker P, Hergesell O, Andrassy K, Van Der Woude FJ. Mycophenolate Mofetil for Maintenance Therapy of Wegener's granulomatosis and microscopic polyangiitis a pilot study in 11 patients with renal involvement. J Ame Soc of Nephrol. 1999 Sep 1;10(9):1965-71.

European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995;345:1321.

Nowak I, Shaw LM. Effect of mycophenolic acid glucuronide on inosine monophosphate dehydrogenase activity. Ther Drug Monit. 1997;19:358.

Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf. 2001;24:645-63. (PMID: 11522119).

Khanna D, Hays RD, Maranian P, Seibold JR, Impens A, Mayes MD, et al. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum. 2009;61:1257-63.

Zeher M, Doria A, Lan J, Aroca G, Jayne D, Boletis I. et al. Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus. 2011;20:1484-93.

Houssiau FA, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010;69:2083-9.

Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365:1886-95.

Mendoza FA, Nagle SJ, Lee JB, Jimenez SA. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol. 2012;39:1241-7.

Derk CT, Grace E, Shenin M, Naik M, Schulz S, Xiong W, et al. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology. 2009;48:1595-9.

Stratton RJ, Wilson H, Black CM. Pilot study of antithymocyte globulin plus mycophenolate mofetil in recent onset diffuse scleroderma. Rheumatology (Oxford). 2001;40:84-8.